Auxilium Biotechnologies Inc.

Auxilium Biotechnologies Inc., a San Diego-based biomedical technology manufacturer, operates exclusively as a prime contractor and federal grant recipient, delivering advanced medical devices and biomanufacturing services to NASA and the National Institutes of Health with no subcontract footprint. The vendor competes on full-and-open basis across all recent awards, with no set-aside designations.

Auxilium's federal capability portfolio centers on space-based drug-delivery device biomanufacturing, neural interface technologies, and advanced biomedical engineering. The vendor holds two definitive contracts with NASA Johnson Space Center: a $9.93 million firm fixed-price contract awarded July 1, 2026, for AUXILIUM Phase 2 (completion April 30, 2029), and a prior $4.67 million contract awarded September 6, 2022, for biomanufacturing of drug-delivery medical devices in space leveraging microgravity conditions on the International Space Station (completion November 30, 2026). Auxilium also holds a $146,794 total small business set-aside definitive contract from the Shared Services Center awarded September 29, 2025, for SBIR Phase I work on microfabrication platform cartridge modification (completion March 27, 2026). Beyond contracts, Auxilium is a prime recipient of a cooperative agreement from the National Institute of Neurological Disorders and Stroke (awarded March 15, 2023, completion August 31, 2027) to develop the NeuroSpan Bridge, a biomimetic multi-channel peripheral nerve repair scaffold designed to accelerate axonal regeneration for combat and trauma-related nerve injuries; the project encompasses pre-clinical studies, FDA IDE application, and feasibility clinical trials.

Customer concentration is heavily NASA-weighted: NASA Johnson Space Center anchors 2 awards worth $14.6 million combined potential value, while the NASA Shared Services Center and NIH's NINDS split the remaining work. Four awards total across four years (2022, 2023, 2025, 2026) represent sparse activity; combined potential value reaches $14.8 million, with $12 million obligated. Two awards face ultimate completion within the next twenty-four months, carrying combined potential value of $4.7 million and representing material recompete exposure. The vendor's NAICS footprint splits between Research and Development in Physical, Engineering, and Life Sciences (two awards) and general science and technology R&D (one award), with PSC coding aligned to space R&D services and general science and technology R&D administrative expenses.

Bioengineering of therapeutic implants using 3D printing